 |
PDBsum entry 1t3r
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Discovery and selection of tmc114, A next generation HIV-1 protease inhibitor.
|
 |
|
Authors
|
 |
D.L.Surleraux,
A.Tahri,
W.G.Verschueren,
G.M.Pille,
H.A.De kock,
T.H.Jonckers,
A.Peeters,
S.De meyer,
H.Azijn,
R.Pauwels,
M.P.De bethune,
N.M.King,
M.Prabu-Jeyabalan,
C.A.Schiffer,
P.B.Wigerinck.
|
 |
|
Ref.
|
 |
J Med Chem, 2005,
48,
1813-1822.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The screening of known HIV-1 protease inhibitors against a panel of
multi-drug-resistant viruses revealed the potent activity of TMC126 on
drug-resistant mutants. In comparison to amprenavir, the improved affinity of
TMC126 is largely the result of one extra hydrogen bond to the backbone of the
protein in the P2 pocket. Modification of the substitution pattern on the
phenylsulfonamide P2' substituent of TMC126 created an interesting SAR, with the
close analogue TMC114 being found to have a similar antiviral activity against
the mutant and the wild-type viruses. X-ray and thermodynamic studies on both
wild-type and mutant enzymes showed an extremely high enthalpy driven affinity
of TMC114 for HIV-1 protease. In vitro selection of mutants resistant to TMC114
starting from wild-type virus proved to be extremely difficult; this was not the
case for other close analogues. Therefore, the extra H-bond to the backbone in
the P2 pocket cannot be the only explanation for the interesting antiviral
profile of TMC114. Absorption studies in animals indicated that TMC114 has
pharmacokinetic properties comparable to currently approved HIV-1 protease
inhibitors.
|
 |
|
|
|
|
 |